Analysts Set Immuneering Co. (NASDAQ:IMRX) Target Price at $12.80

Immuneering Co. (NASDAQ:IMRX) has received a consensus rating of “Hold” from the eight ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $12.80.

Several analysts recently issued reports on IMRX shares. Morgan Stanley cut Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of Immuneering in a research report on Monday, January 13th. Finally, Chardan Capital restated a “buy” rating and set a $13.00 target price on shares of Immuneering in a report on Wednesday, January 8th.

Institutional Investors Weigh In On Immuneering

Several hedge funds and other institutional investors have recently made changes to their positions in IMRX. Vontobel Holding Ltd. purchased a new position in Immuneering during the third quarter valued at $25,000. Corsair Capital Management L.P. bought a new position in shares of Immuneering in the third quarter worth about $25,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Immuneering during the 2nd quarter valued at about $44,000. Tidemark LLC bought a new position in shares of Immuneering during the 3rd quarter valued at approximately $129,000. Finally, HighTower Advisors LLC increased its holdings in Immuneering by 21.4% in the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock worth $132,000 after acquiring an additional 9,400 shares in the last quarter. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Trading Down 2.1 %

NASDAQ IMRX opened at $1.91 on Monday. The firm has a market cap of $59.31 million, a PE ratio of -0.97 and a beta of -0.36. Immuneering has a 1-year low of $1.00 and a 1-year high of $7.68. The stock has a 50-day moving average of $2.06 and a 200-day moving average of $1.87.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.